Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "WFRF:(Katus Hugo A) "

Sökning: WFRF:(Katus Hugo A)

  • Resultat 1-10 av 55
  • [1]23456Nästa
Sortera/gruppera träfflistan
  • Bueno, Hector, et al. (författare)
  • Report of the European Society of Cardiology Cardiovascular Round Table regulatory workshop update of the evaluation of new agents for the treatment of acute coronary syndrome : Executive summary
  • 2019
  • Ingår i: European heart journal. Acute cardiovascular care.. - : SAGE PUBLICATIONS LTD. - 2048-8726. ; 8:8, s. 745-754
  • Tidskriftsartikel (refereegranskat)abstract
    • Regulatory authorities interpret the results of randomized controlled trials according to published principles. The European Medicines Agency (EMA) is planning a revision of the 2000 and 2003 guidance documents on clinical investigation of new medicinal products for the treatment of acute coronary syndrome (ACS) to achieve consistency with current knowledge in the field. This manuscript summarizes the key output from a collaborative workshop, organized by the Cardiovascular Round Table and the European Affairs Committee of the European Society of Cardiology, involving clinicians, academic researchers, trialists, European and US regulators, and pharmaceutical industry researchers. Specific questions in four key areas were selected as priorities for changes in regulatory guidance: patient selection, endpoints, methodologic issues and issues related to the research for novel agents. Patients with ST-segment elevation myocardial infarction (STEMI) and non-STEMI (NSTEMI) should be studied separately for therapies aimed at the specific pathophysiology of either condition, particularly for treatment of the acute phase, but can be studied together for other treatments, especially long-term therapy. Unstable angina patients should be excluded from acute phase ACS trials. In general, cardiovascular death and reinfarction are recommended for primary efficacy endpoints; other endpoints may be considered if specifically relevant for the therapy under study. New agents or interventions should be tested against a background of evidence-based therapy with expanded follow-up for safety assessment. In conclusion, new guidance documents for randomized controlled trials in ACS should consider changes regarding patient and endpoint selection and definitions, and trial designs. Specific requirements for the evaluation of novel pharmacological therapies need further clarification.
  • Franchi, Francesco, et al. (författare)
  • Impact of Diabetes Mellitus and Chronic Kidney Disease on Cardiovascular Outcomes and Platelet P2Y12 Receptor Antagonist Effects in Patients With Acute Coronary Syndromes : Insights From the PLATO Trial
  • 2019
  • Ingår i: Journal of the American Heart Association. - 2047-9980 .- 2047-9980. ; 8:6
  • Tidskriftsartikel (refereegranskat)abstract
    • Background-There are limited data on how the combination of diabetes mellitus (DM) and chronic kidney disease (CKD) affects cardiovascular outcomes as well as response to different P2Y(12) receptor antagonists, which represented the aim of the present investigation. Methods and Results-In this post hoc analysis of the PLATO (Platelet Inhibition and Patient Outcomes) trial, which randomized acute coronary syndrome patients to ticagrelor versus clopidogrel, patients (n=15 108) with available DM and CKD status were classified into 4 groups: DM+/CKD+ (n=1058), DM+/CKD- (n=2748), DM-/CKD+ (n=2160), and DM-/CKD- (n=9142). The primary efficacy end point was a composite of cardiovascular death, myocardial infarction, or stroke at 12 months. The primary safety end point was PLATO major bleeding. DM+/CKD+ patients had a higher incidence of the primary end point compared with DM-/CKD- patients (23.3% versus 7.1%; adjusted hazard ratio 2.22; 95% CI 1.88-2.63; P<0.001). Patients with DM+/CKD- and DM-/CKD+ had an intermediate risk profile. The same trend was shown for the individual components of the primary end point and for major bleeding. Compared with clopidogrel, ticagrelor reduced the incidence of the primary end point consistently across subgroups (P-interaction=0.264), but with an increased absolute risk reduction in DM+/CKD+. The effects on major bleeding were also consistent across subgroups (P-interaction=0.288). Conclusions-In acute coronary syndrome patients, a gradient of risk was observed according to the presence or absence of DM and CKD, with patients having both risk factors at the highest risk. Although the ischemic benefit of ticagrelor over clopidogrel was consistent in all subgroups, the absolute risk reduction was greatest in patients with both DM and CKD.
  • Katus, Hugo, et al. (författare)
  • Early diagnosis of acute coronary syndrome
  • 2017
  • Ingår i: European Heart Journal. - 0195-668X .- 1522-9645. ; 38:41, s. 3049-3055
  • Forskningsöversikt (refereegranskat)abstract
    • The diagnostic evaluation of acute chest pain has been augmented in recent years by advances in the sensitivity and precision of cardiac troponin assays, new biomarkers, improvements in imaging modalities, and release of new clinical decision algorithms. This progress has enabled physicians to diagnose or rule-out acute myocardial infarction earlier after the initial patient presentation, usually in emergency department settings, which may facilitate prompt initiation of evidence-based treatments, investigation of alternative diagnoses for chest pain, or discharge, and permit better utilization of healthcare resources. A non-trivial proportion of patients fall in an indeterminate category according to rule-out algorithms, and minimal evidence-based guidance exists for the optimal evaluation, monitoring, and treatment of these patients. The Cardiovascular Round Table of the ESC proposes approaches for the optimal application of early strategies in clinical practice to improve patient care following the review of recent advances in the early diagnosis of acute coronary syndrome. The following specific 'indeterminate' patient categories were considered: (i) patients with symptoms and high-sensitivity cardiac troponin <99th percentile; (ii) patients with symptoms and high-sensitivity troponin <99th percentile but above the limit of detection; (iii) patients with symptoms and high-sensitivity troponin >99th percentile but without dynamic change; and (iv) patients with symptoms and high-sensitivity troponin >99th percentile and dynamic change but without coronary plaque rupture/erosion/dissection. Definitive evidence is currently lacking to manage these patients whose early diagnosis is 'indeterminate' and these areas of uncertainty should be assigned a high priority for research.
  • Haas, Jan, et al. (författare)
  • Atlas of the clinical genetics of human dilated cardiomyopathy
  • 2015
  • Ingår i: European Heart Journal. - : Oxford University Press. - 0195-668X .- 1522-9645. ; 36:18, s. 1123-U43
  • Tidskriftsartikel (refereegranskat)abstract
    • Aim: We were able to show that targeted Next-Generation Sequencing is well suited to be applied in clinical routine diagnostics, substantiating the ongoing paradigm shift from low- to high-throughput genomics in medicine. By means of our atlas of the genetics of human DCM, we aspire to soon be able to apply our findings to the individual patient with cardiomyopathy in daily clinical practice. Numerous genes are known to cause dilated cardiomyopathy (DCM). However, until now technological limitations have hindered elucidation of the contribution of all clinically relevant disease genes to DCM phenotypes in larger cohorts. We now utilized next-generation sequencing to overcome these limitations and screened all DCM disease genes in a large cohort. Methods and results: In this multi-centre, multi-national study, we have enrolled 639 patients with sporadic or familial DCM. To all samples, we applied a standardized protocol for ultra-high coverage next-generation sequencing of 84 genes, leading to 99.1% coverage of the target region with at least 50-fold and a mean read depth of 2415. In this well characterized cohort, we find the highest number of known cardiomyopathy mutations in plakophilin-2, myosin-binding protein C-3, and desmoplakin. When we include yet unknown but predicted disease variants, we find titin, plakophilin-2, myosin-binding protein-C 3, desmoplakin, ryanodine receptor 2, desmocollin-2, desmoglein-2, and SCN5A variants among the most commonly mutated genes. The overlap between DCM, hypertrophic cardiomyopathy (HCM), and channelopathy causing mutations is considerably high. Of note, we find that >38% of patients have compound or combined mutations and 12.8% have three or even more mutations. When comparing patients recruited in the eight participating European countries we find remarkably little differences in mutation frequencies and affected genes. Conclusion: This is to our knowledge, the first study that comprehensively investigated the genetics of DCM in a large-scale cohort and across a broad gene panel of the known DCM genes. Our results underline the high analytical quality and feasibility of Next-Generation Sequencing in clinical genetic diagnostics and provide a sound database of the genetic causes of DCM.
  • Mueller-Hennessen, Matthias, et al. (författare)
  • Combined testing of copeptin and high-sensitivity cardiac troponin T at presentation in comparison to other algorithms for rapid rule-out of acute myocardial infarction
  • 2019
  • Ingår i: International Journal of Cardiology. - 0167-5273 .- 1874-1754. ; 276, s. 261-267
  • Tidskriftsartikel (refereegranskat)abstract
    • BACKGROUND: We aimed to directly compare the diagnostic and prognostic performance of a dual maker strategy (DMS) with combined testing of copeptin and high-sensitivity (hs) cardiac troponin T (cTnT) at time of presentation with other algorithms for rapid rule-out of acute myocardial infarction (AMI).METHODS: 922 patients presenting to the emergency department with suspected AMI and available baseline copeptin measurements qualified for the present TRAPID-AMI substudy. Diagnostic measures using the DMS (copeptin <10, <14 or < 20 pmol/L and hs-cTnT≤14 ng/L), the 1 h-algorithm (hs-cTnT<12 ng/L and change <3 ng/L at 1 h), as well as the hs-cTnT limit-of-blank (LoB, <3 ng/L) and -detection (LoD, <5 ng/L) were compared. Outcomes were assessed as combined end-points of death and myocardial re-infarction.RESULTS: True-negative rule-out using the DMS could be achieved in 50.9%-62.3% of all patients compared to 35.0%, 45.3% and 64.5% using LoB, LoD or the 1 h-algorithm, respectively. The DMS showed NPVs of 98.1%-98.3% compared to 99.2% for the 1 h-algorithm, 99.4% for the LoB and 99.3% for the LoD. Sensitivities were 93.5%-94.8%, as well as 96.8%, 98.7% and 98.1%, respectively. Addition of clinical low-risk criteria such as a HEART-score ≤ 3 to the DMS resulted in NPVs and sensitivities of 100% with a true-negative rule-out to 33.8%-41.6%. Rates of the combined end-point of death/MI within 30 days ranged between 0.2% and 0.3% for all fast-rule-out protocols.CONCLUSION: Depending on the applied copeptin cut-off and addition of clinical low-risk criteria, the DMS might be an alternative to the hs-cTn-only-based algorithms for rapid AMI rule-out with comparable diagnostic measures and outcomes.
Skapa referenser, mejla, bekava och länka
  • Resultat 1-10 av 55
  • [1]23456Nästa
Typ av publikation
tidskriftsartikel (53)
annan publikation (1)
forskningsöversikt (1)
Typ av innehåll
refereegranskat (51)
övrigt vetenskapligt (4)
Katus, Hugo A (45)
Storey, Robert F. (39)
Becker, Richard C. (28)
Himmelmann, Anders (25)
Wallentin, Lars (23)
Cannon, Christopher ... (21)
visa fler...
Harrington, Robert A ... (20)
Husted, Steen (20)
Steg, Philippe Gabri ... (19)
James, Stefan K (17)
Wallentin, Lars, 194 ... (16)
Katus, Hugo (11)
Siegbahn, Agneta (10)
Giannitsis, Evangelo ... (9)
Steg, Ph Gabriel (9)
James, Stefan K, 196 ... (8)
James, Stefan (8)
Mahaffey, Kenneth W. (8)
Horrow, Jay (8)
Budaj, Andrzej (8)
James, Stefan, 1964- (7)
Armstrong, Paul W. (7)
Morais, Joao (7)
Jaffe, Allan S. (7)
Hagström, Emil (6)
Lindahl, Bertil (6)
Cornel, Jan H. (6)
Varenhorst, Christop ... (6)
Ardissino, Diego (6)
Eriksson, Niclas (5)
Tendera, Michal (5)
Johansson, Åsa (5)
Lewis, Basil S. (5)
Wojdyla, Daniel M. (5)
Held, Claes (5)
Siegbahn, Agneta, 19 ... (5)
Axelsson, Tomas (4)
Syvänen, Ann-Christi ... (4)
Lindahl, Bertil, 195 ... (4)
Bertilsson, Maria (4)
Mueller, Christian (4)
Emanuelsson, Håkan (4)
White, Harvey D. (4)
Åkerblom, Axel, 1977 ... (4)
Thygesen, Kristian (4)
Newby, L Kristin (4)
Simoons, Maarten L (4)
Hamm, Christian W. (4)
Bassand, Jean-Pierre (4)
Bax, Jeroen J (4)
visa färre...
Uppsala universitet (53)
Karolinska Institutet (2)
Göteborgs universitet (1)
Umeå universitet (1)
Lunds universitet (1)
Engelska (55)
Forskningsämne (UKÄ/SCB)
Medicin och hälsovetenskap (34)
Naturvetenskap (1)


pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy